AR009757A1 - USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO( - Google Patents
USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO(Info
- Publication number
- AR009757A1 AR009757A1 ARP970104168A ARP970104168A AR009757A1 AR 009757 A1 AR009757 A1 AR 009757A1 AR P970104168 A ARP970104168 A AR P970104168A AR P970104168 A ARP970104168 A AR P970104168A AR 009757 A1 AR009757 A1 AR 009757A1
- Authority
- AR
- Argentina
- Prior art keywords
- cetrorelix
- prostate cancer
- alpha
- bph
- medication
- Prior art date
Links
- 229960003230 cetrorelix Drugs 0.000 title abstract 5
- 108700008462 cetrorelix Proteins 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 3
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- -1 CETRORELIX COMPOUND Chemical class 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000003087 receptor blocking agent Substances 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se trata de preparaciones farmacéuticas que permiten el manejo terapéutico de hiperplasias prostáticas benigna y del cáncer de prostata. Dichaspreparaciones comprenden Cetrorelix, opcionalmente en combinacion con inhibidores de alfa-reductasa o agentes bloqueadores de receptores alfa. Dichaspreparaciones con dicho régimen permiten reducir el volumen de la prostata y evita los efectos colaterales que acompanan los niveles de testosterona que seencuentra en el ámbito de castracion. El Cetrorelix es administrado a dosis de entre 0,5 mg/día y 20 mg/semana o alrededor de 0,014 mg/Kg de peso corporal pordía a 0,30 mg/Kg de peso corporal por semana o a niveles de alrededor de 25 a 120 mg de Cetrorelix por mes o 0,376 mg/Kg a 1,71mg/Kg por mes. El Cetrorelixpuede ser administrado con con inhibidores de alfa-reductasa o agentes bloqueadores de receptores alfa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2599096P | 1996-09-12 | 1996-09-12 | |
| US4322897P | 1997-04-10 | 1997-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009757A1 true AR009757A1 (es) | 2000-05-03 |
Family
ID=26700570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104168A AR009757A1 (es) | 1996-09-12 | 1997-09-11 | USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO( |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US6054432A (es) |
| EP (1) | EP0925069B1 (es) |
| JP (1) | JP2001500500A (es) |
| KR (1) | KR100546235B1 (es) |
| CN (1) | CN1126566C (es) |
| AR (1) | AR009757A1 (es) |
| AT (1) | ATE370743T1 (es) |
| AU (1) | AU738306B2 (es) |
| BR (1) | BR9713197A (es) |
| CA (1) | CA2215015A1 (es) |
| CZ (1) | CZ298738B6 (es) |
| DE (1) | DE69738045T2 (es) |
| DK (1) | DK0925069T3 (es) |
| EE (1) | EE04000B1 (es) |
| ES (1) | ES2289764T3 (es) |
| HU (1) | HUP0000261A3 (es) |
| IL (3) | IL128331A0 (es) |
| IS (1) | IS4978A (es) |
| MX (1) | MXPA99002420A (es) |
| NO (1) | NO326207B1 (es) |
| NZ (1) | NZ334540A (es) |
| PL (1) | PL193184B1 (es) |
| PT (1) | PT925069E (es) |
| RU (1) | RU2215537C2 (es) |
| SK (1) | SK286174B6 (es) |
| TR (1) | TR199900556T2 (es) |
| TW (1) | TWI224002B (es) |
| WO (1) | WO1998010781A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
| FR2768055A1 (fr) * | 1997-09-11 | 1999-03-12 | Synthelabo | Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie |
| TW536402B (en) * | 1998-06-26 | 2003-06-11 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for the therapy of voiding dysfunction |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| US7129262B2 (en) * | 1999-07-23 | 2006-10-31 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| US7105560B1 (en) | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
| US7151100B1 (en) * | 1999-07-23 | 2006-12-19 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| US7361680B2 (en) * | 1999-07-23 | 2008-04-22 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| ID30249A (id) * | 1999-08-09 | 2001-11-15 | Yamanouchi Pharma Co Ltd | Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah |
| CA2669753C (en) | 1999-09-30 | 2012-06-26 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| DE10040700A1 (de) * | 2000-08-17 | 2002-02-28 | Asta Medica Ag | Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung |
| KR100876538B1 (ko) * | 2000-08-17 | 2008-12-31 | 아에테르나 젠타리스 게엠베하 | Ｌｈｒｈ 길항제의 염의 제조방법 |
| JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| US7211599B2 (en) * | 2002-09-19 | 2007-05-01 | The Regents Of The University Of California | Use of etodolac to treat hyperplasia |
| GB0301016D0 (en) * | 2003-01-16 | 2003-02-19 | Univ London | Treatment of benign prostatic hyperplasia |
| MXPA05007572A (es) | 2003-01-17 | 2005-11-17 | Threshold Pharmaceuticals Inc | Tratamiento de hiperplasia prostatica benigna. |
| CN101677975B (zh) * | 2006-05-03 | 2013-06-26 | 威斯康星校友研究基金会 | N1,n4-双(丁-1,3-二烯基)丁-1,4-二胺药物组合物及其方法 |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| US10585101B2 (en) | 2016-03-10 | 2020-03-10 | Wavesense, Inc. | Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2465486A1 (fr) * | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| HU199694B (en) * | 1988-05-10 | 1990-03-28 | Innofinance Altalanos Innovaci | Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives |
| DE3918543A1 (de) * | 1989-06-07 | 1990-12-13 | Boehringer Mannheim Gmbh | Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie |
| IL101245A0 (en) * | 1991-03-20 | 1992-11-15 | Merck & Co Inc | Pharmaceutical compositions for the treatment of prostatic cancer |
| IL101243A (en) * | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
-
1997
- 1997-08-07 US US08/908,198 patent/US6054432A/en not_active Expired - Fee Related
- 1997-09-01 MX MXPA99002420A patent/MXPA99002420A/es unknown
- 1997-09-01 EE EEP199900121A patent/EE04000B1/xx not_active IP Right Cessation
- 1997-09-01 RU RU99107280/14A patent/RU2215537C2/ru not_active IP Right Cessation
- 1997-09-01 CN CN97197904A patent/CN1126566C/zh not_active Expired - Fee Related
- 1997-09-01 BR BR9713197-0A patent/BR9713197A/pt not_active Application Discontinuation
- 1997-09-01 KR KR1019997002053A patent/KR100546235B1/ko not_active Expired - Lifetime
- 1997-09-01 ES ES97944818T patent/ES2289764T3/es not_active Expired - Lifetime
- 1997-09-01 SK SK301-99A patent/SK286174B6/sk not_active IP Right Cessation
- 1997-09-01 JP JP10513204A patent/JP2001500500A/ja active Pending
- 1997-09-01 AT AT97944818T patent/ATE370743T1/de not_active IP Right Cessation
- 1997-09-01 CZ CZ80899A patent/CZ298738B6/cs not_active IP Right Cessation
- 1997-09-01 EP EP97944818A patent/EP0925069B1/en not_active Expired - Lifetime
- 1997-09-01 DE DE69738045T patent/DE69738045T2/de not_active Expired - Lifetime
- 1997-09-01 PL PL332085A patent/PL193184B1/pl not_active IP Right Cessation
- 1997-09-01 IL IL12833197A patent/IL128331A0/xx unknown
- 1997-09-01 WO PCT/EP1997/004740 patent/WO1998010781A1/en not_active Ceased
- 1997-09-01 NZ NZ334540A patent/NZ334540A/xx unknown
- 1997-09-01 AU AU46198/97A patent/AU738306B2/en not_active Ceased
- 1997-09-01 HU HU0000261A patent/HUP0000261A3/hu unknown
- 1997-09-01 DK DK97944818T patent/DK0925069T3/da active
- 1997-09-01 PT PT97944818T patent/PT925069E/pt unknown
- 1997-09-01 TR TR1999/00556T patent/TR199900556T2/xx unknown
- 1997-09-10 TW TW086113121A patent/TWI224002B/zh active
- 1997-09-10 CA CA002215015A patent/CA2215015A1/en not_active Abandoned
- 1997-09-11 AR ARP970104168A patent/AR009757A1/es not_active Application Discontinuation
-
1998
- 1998-04-09 US US09/057,458 patent/US5998377A/en not_active Expired - Fee Related
- 1998-04-20 US US09/062,704 patent/US6071882A/en not_active Expired - Fee Related
-
1999
- 1999-02-02 IL IL128331A patent/IL128331A/en not_active IP Right Cessation
- 1999-02-16 IS IS4978A patent/IS4978A/is unknown
- 1999-03-11 NO NO19991192A patent/NO326207B1/no not_active IP Right Cessation
- 1999-09-22 US US09/401,851 patent/US6300313B1/en not_active Expired - Fee Related
-
2008
- 2008-01-30 IL IL189132A patent/IL189132A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009757A1 (es) | USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO( | |
| Hengst et al. | Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors | |
| DE69434416D1 (de) | Präparate auf purinbasis | |
| TR199901544T2 (xx) | Kontrast ajanlar�ndaki veya kontrast ajanlar�yla ilgili geli�meler. | |
| ES2177609T3 (es) | Pluma de administracion de medicacion con una escala para fijacion de la dosis. | |
| EP1370253B8 (en) | Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity | |
| IL142728A0 (en) | The use of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases | |
| ATE298562T1 (de) | Hydrogelpartikel formulierungen | |
| UA42806C2 (uk) | Система для одночасного трансдермального введення кількох активних начал | |
| IL116465A0 (en) | Pharmaceutical antitumor composition | |
| EP0722324A4 (en) | PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY | |
| MY116474A (en) | Potentiation of temozolomide in human tumour cells | |
| Coughlin et al. | Platinum based combined modality approach for locally advanced head and neck carcinoma | |
| Zagon et al. | Naloxone prolongs the survival time of mice treated with neuroblastoma | |
| IT1255723B (it) | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
| NZ511280A (en) | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists | |
| Klocker et al. | Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck | |
| UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
| Heaton et al. | Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy | |
| Shiohara et al. | Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer. | |
| ES2303811T1 (es) | Uso de anastrozol para el tratamiento post-menopausico de una mujer que tiene cancer de mama temprano. | |
| ES2107431T3 (es) | Agentes con accion selectiva sobre los receptores de la adenosina. | |
| Wojciechowski et al. | Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |